A China‑led phase II trial has produced encouraging early results for a new combination approach in extensive‑stage small‑cell lung cancer (ES‑SCLC), a disease long resistant to durable treatments. Investigators led by Professor Zhou Caicun at Tongji University’s affiliated Eastern Hospital tested an EGFR×HER3 bispecific antibody‑drug conjugate called iza‑bren together with a domestically developed anti‑PD‑1 monoclonal antibody (reported as Sru‑li, 斯鲁利单抗) as first‑line therapy.
The study reported that, at an iza‑bren dose of 2.5 mg/kg given on days 1 and 8 every three weeks (D1D8 Q3W), the combination achieved a median progression‑free survival (PFS) of 8.2 months and a one‑year overall survival (OS) rate of 85.7%. The announcement frames these outcomes as the first clinical data supporting an ADC plus PD‑1 inhibitor regimen as frontline therapy for ES‑SCLC and suggests the combination could challenge existing standards.
Those existing standards currently rely on platinum‑etoposide chemotherapy with the addition of PD‑L1 inhibitors such as atezolizumab or durvalumab, which in pivotal trials produced median PFS in the roughly 5‑6 month range. Against that historical backdrop, a median PFS of 8.2 months and an unusually high one‑year OS rate would be notable—provided the data hold up in larger, randomized studies.
The biological rationale for the combination is straightforward: antibody‑drug conjugates (ADCs) deliver cytotoxic payloads selectively to tumor cells via antigen targeting, while immune‑checkpoint blockade can extend and amplify anti‑tumor immune responses. A bispecific ADC directed at both EGFR and HER3 aims to broaden the targeting footprint in tumours where single‑antigen expression can be heterogeneous, potentially increasing response rates when paired with PD‑1 blockade.
Caveats are important. The report does not include peer‑reviewed publication details, safety and adverse‑event profiles, patient numbers, or biomarker stratification, all of which are essential to judging the robustness and generalisability of the findings. Early‑phase trials often show promising efficacy that narrows in larger randomized testing; toxicity from ADC payloads and immune‑related adverse events from PD‑1 inhibitors can also limit applicability.
If subsequently validated in phase III trials, the combination could alter the treatment paradigm for ES‑SCLC, offering a non‑chemotherapy or chemotherapy‑sparing option that improves disease control and survival. Commercially, success would buoy China’s biopharma sector by showcasing an indigenous ADC paired with a domestic PD‑1 agent, with implications for regulatory approval, pricing and global market competition.
For clinicians and patients, the immediate takeaway is cautious optimism. The data signal that next‑generation biologics and targeted cytotoxics can meaningfully deepen responses in a cancer subtype with historically poor outcomes, but confirmation from larger trials with full safety and subgroup analyses is critical before practice changes.